secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001576885-24-000039
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen reports $306M cash, runway into H1 2027; plans Phase 2-only ALTITUDE-AD study
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities ~$306M as of Dec 31, 2023 (preliminary, unaudited).
- Company expects cash to fund operations into first half of 2027.
- Anticipates amending ALTITUDE-AD Phase 2/3 protocol to a standalone Phase 2 study.
- Updated corporate presentation posted on investor website on March 19, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000039/0001576885-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000039/abos-20240319.htm
  HTML page:      https://secwatch.observer/filing/0001576885-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer